ClinicalTrials.gg
RecruitingNCT05991791I-ROBIUpdated Nov 13, 2023

Intelligent Robotic Interactions for Children With Autism Spectrum Disorders

An interventional study of Early Start Denver Model (ESDM) in Autism Spectrum Disorder, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2023-11-13.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
2 Years to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Autism Spectrum Disorder by University Hospital, Montpellier — 5 open to participants now, 6 under way, none of them phase 3. Autism Spectrum Disorder · University Hospital, Montpellier.

Started
2023
with 2 others
No phase
6 of 12
2 open now
Registered
11th of 12
by date

Among the 12 studies in Autism Spectrum Disorder by University Hospital, Montpellier, this one is one of 3 that started in 2023, is one of 6 with no phase, and was the 11th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

5 of the 12 studies in Autism Spectrum Disorder by University Hospital, Montpellier are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 2 Years to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Autism Spectrum Disorder by University Hospital, Montpellier, or all of them as a file.
02

Study summary

For several years, studies have been developed on the contribution of social robots as a tool for interventions for children with autism spectrum disorders (ASD). One of the recommended intervention models is the ESDM (Early Start Denver Model). It consists of setting up an individualized, intensive program (at least 20 hours per week) through the pleasure of play. The teacher follows the motivation and interests of the child, and it is the child who chooses the activities. Studies published in recent years tend to show that robots bring benefits to ASD children, particularly in the treatment of social interactions and in clinical settings. However, there is no scientific consensus on the generalized contribution and effect over time of these interventions. Moreover, a robotic solution controlled by a practitioner through a telepresence system allows for a better adaptability to the responses and desires of the children during the interventions. The investigators believe that such a solution would allow for better assessment of progress in the core skills of expressive communication and imitation and greater engagement during interventions.

03

Conditions studied

  • Autism Spectrum Disorder

Keywords

  • Autism spectrum disorder
  • children
  • interventional care
  • robotics
  • telepresence
04

Who can participate

Ages eligible
2 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient living in the Hérault department (France),
  • Patient with a diagnosis of ASD confirmed by a psychiatrist or a psychologist and receiving current care according to the ESDM model in the MPEA Peyre Plantade child psychiatry service.

Exclusion criteria

Exclusion Criteria:

  • Patients

    • Failure to obtain written after a cooling-off period
    • Participating in another type of program other than ESDM
    • Not being affiliated to a French social security system or being a beneficiary of such a system
  • Therapist

    • History of epilepsy for health professionals (therapists)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Other
    Children with autism spectrum disorders

    Other: Early Start Denver Model (ESDM)

Interventions

  • OtherEarly Start Denver Model (ESDM)

    Phase A * 4 individual sessions (1 per week) * Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM * Satisfaction Evaluation - Parent * Satisfaction Evaluation - Therapist Phase B : * 11 sessions (1 per week) * Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM with the help of the robot Pepper * Satisfaction Evaluation - Parent * Satisfaction Evaluation - Therapist Phase C : * 4 sessions (1 per week) * Additional time of 15 minutes to evaluate 3 selected tasks of the ESDM without the help of the robot Pepper * Satisfaction Evaluation - Parent * Satisfaction Evaluation - Therapist * All sessions will also be filmed and recorded

06

What researchers measure

Primary outcomes

  1. Score of success on the selected task in the ESDM program

    Measure the success score for the selected task using the ESDM scoring grid. As soon as the child successfully completes one of the different learning stages, a success score is given to the task. This score will be maximum if all the learning stages of the task considered have been reached (Task 1 = 6 learning stages (maximum score =6); Tasks 2 and 3 = 7 stages (maximum score =7)). The ESDM scoring grid will be completed by the research therapists at the end of each session.

    Time frame: From phase A (baseline) to phase C (post-intervention) = 19 weeks

Secondary outcomes

  1. Time of the child's viewing and movement of the head and body towards the robot (task 1: saying "hello")

    Measurement of the viewing and movement times toward the robot, as well as the response time from the analysis of the videos made during the sessions using the Pepper robot. Data from the robot: - Video recording by camera of the sessions of the whole room (camera independent of the robot) - Video return by the camera installed on the robot - Audio feedback from the therapist, the robot and the child.

    Time frame: During Phase B = 11 weeks

Other outcomes

  1. Time of the child's viewing and movement of the head and body towards the therapist (task 1: saying "hello")

    Measurement of the viewing and movement times toward the therapist, as well as the response time from the analysis of the videos made during the sessions using the Pepper robot. Data from the robot: - Video recording by camera of the sessions of the whole room (camera independent of the robot) - Video return by the camera installed on the robot - Audio feedback from the therapist, the robot and the child.

    Time frame: From phase A (baseline) to phase C (post-intervention) = 19 weeks

  2. Response time of the child after the presentation of the imitation exercise (task 2: action imitation)

    Measurement of the child's response time during the imitation exercise

    Time frame: From phase A (baseline) to phase C (post-intervention) = 19 weeks

  3. Number of objects given to the robot (task 3 : give an object on verbal request)

    Measurement of the number of objects given out of the 5 requested (best score 5/5) in task 3.

    Time frame: From phase A (baseline) to phase C (post-intervention) = 19 weeks

  4. Teleoperation success score for therapist (throught UX score)

    Measurement of the success score (UX) of the teleoperation using the videos of the Pepper robot and according to the successful tasks to be performed during the session (the child and the second practitioner in the room can clearly hear the robot's instructions, the robot's gestures are fluid and is able to point to objects with the hand...). If the therapist was able to initiate each task, the score is 3/3.

    Time frame: Phase C (from week 5 to 15)

  5. Parent satisfaction score on current care

    Measurement of satisfaction score using a numerical satisfaction scale (EN). Parents will be asked about their current satisfaction with the care after each phase of the procedure. This will be rated on a scale of 0 to 10, (0 "I am not at all satisfied with the effectiveness of the proposed care" and 10 "I am totally satisfied with the care").

    Time frame: During phase A (to 4 weeks), Phase B (to 15 weeks), Phase C (to 19 weeks).

  6. Professional satisfaction score on current care.

    Measurement of satisfaction score using a numerical satisfaction scale (EN). Professionals will be asked about their current satisfaction with the care after each phase of the procedure. This will be rated on a scale of 0 to 10, (0 "I am not at all satisfied with the effectiveness of the proposed care" and 10 "I am totally satisfied with the care").

    Time frame: During phase A (to 4 weeks), Phase B (to 15 weeks), Phase C (to 19 weeks)

  7. Score of success in the ESDM tasks without teleoperation

    This score (observe/total) will be maximum if all the learning stages of the task in question have been reached (Task 1 = 6 learning stages (maximum score =6); Tasks 2 and 3 = 7 stages (maximum score = 7)). This scoring will be done by therapist at the end of each intervention, after the current care.

    Time frame: During phase A (to 4 weeks), Phase C (from week 16 to 19

  8. Score of success in the ESDM tasks with teleoperation

    This score (observe/total) will be maximum if all the learning stages of the task in question have been reached (Task 1 = 6 learning stages (maximum score =6); Tasks 2 and 3 = 7 stages (maximum score =7)).The robotics analyses will be performed by a robotic engineer of the LIRMM independent to the project.

    Time frame: During phase B (from week 5 to 15)

  9. Teleoperation usability score for therapist (throught UMUX score)

    A User Experience Questionnaire (UMUX) was administered at weeks 5, 10 and 15 to assess the quality and ease of use of the teleoperation system over time. The questionnaires are evaluated on a scale from 0 (minimum score) to 10 (maximum score). 0=Not at all satisfied 10= Totally satisfied

    Time frame: During phase A (to 4 weeks), Phase B (to 15 weeks), Phase C (to 19 weeks)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Mar 2025, 17 months after the start.

Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 17 months is below that.

Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2023
First posted
Aug 15, 2023
StartActual
Oct 19, 2023
Primary completionEst.
Mar 19, 2025
CompletionEst.
Sep 19, 2025
Last update
Nov 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05991791
Collaborators
Centre National de la Recherche Scientifique, France
Responsible party
Sponsor
First posted
Aug 15, 2023
Start date
Oct 19, 2023
Primary completion
Mar 19, 2025 (estimated)
Completion
Sep 19, 2025 (estimated)
Last update
Nov 13, 2023

Study contacts

Amaria BAGHDADLI, Pr
Contact
a-baghdadli@chu-montpellier.fr
04 67 33 96 96

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion